WDNA241220C17000
- 0.00
- 0.000.00%
WISDOMTREE BIOREVOLUTION FUND Newsroom
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Musk causes a commotion at Capitol Hill, is a "Trump 2.0" prototype emerging?
Analysis suggests that Musk's recent act of detonating a political nuclear bomb may be a rehearsal for the Trump 2.0 era of Musk's action model, intended to exert pressure on Congress. However, some also say that the consensus at Mar-a-Lago is that Musk has proven to be an effective Weapon to pressure Congress and a scapegoat for any backlash.
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
Pfizer Gets FDA Accelerated Approval for Braftovi
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
J.P. Morgan's Top Healthcare Stocks for 2025
Benzinga Market Summary: Novo Nordisk Falls On Weight Loss Data, Shares Of Competitor Lilly Rise, S&P Continues Higher
US Stock Preview | USA PCE data overall underperformed expectations, and the declines in the three major futures indices significantly narrowed; US stocks face another test: the largest "Triple Witching" day in history arrives tonight!
The latest weight loss drug's phase 3 trial results were below expectations, resulting in Novo-Nordisk A/S's shares dropping nearly 20% in Pre-Market Trading; the Trump Media Technology Group's shares fell over 4% in Pre-Market Trading as Trump transferred all his shares to a revocable REITs.
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
The weight loss effect of the new drug was below expectations, and Novo-Nordisk A/S saw its stock plummet by 28% in Pre-Market Trading, while competitor Eli Lilly and Co surged over 12%.
The experimental results show that patients who received subcutaneous injections of CagriSema lost an average of 22.7% of their weight after 68 weeks. If volunteers who dropped out of the trial are included, the average weight loss effect decreases to 20.4%, both below the company's previous expectation of 25%.
Novo Nordisk New Obesity Therapy CagriSema Outperforms Semaglutide in Phase 3 Trial
Express News | Novo-Nordisk A/S fell 27% in Pre-Market Trading as the results of its weight loss drug trials fell short of expectations, while competitor Eli Lilly and Co surged over 9%.
The Dow barely ended its longest continuous decline in 50 years, Micron fell by 16%, the US dollar reached a two-year high again, and US bonds, oil, and Bitcoin all dropped.
U.S. stock market's other Indexes turned down towards the end, Tesla rose by nearly 4% before closing down, NVIDIA reached a high of 4%, and Micron Technology had its steepest decline in five years. The yield on the 10-year U.S. Treasury bonds briefly increased by nearly 10 basis points approaching 4.60%, close to a seven-month high, while short-term bond yields fell, with the 2/10-year yield spread at its widest in two and a half years. The Bank of England held rates steady, but more officials supported a rate cut, leading to a decline in the British Pound. The Governor of the Bank of Japan suppressed interest rate hike expectations, causing the yen to fall towards 158, and the offshore renminbi briefly dropped below 7.32 yuan to its lowest in 15 months. Bitcoin fell by 5%, approaching $0.096 million. Spot Gold rose by 1.6% before narrowing back below $2,600, while the futures silver fell by 5%, and U.S. crude oil fell below $70.
U.S. Healthcare Spending Climbs 7.5% in 2023
The FDA announced that Eli Lilly and Co's weight loss drug ingredients are no longer in short supply, and compound pharmacies will stop producing generic drugs.
The USA FDA announced that Eli Lilly and Co's weight loss drug Zepbound's active ingredient tirzepatide is no longer in shortage, and compounding pharmacies will no longer be allowed to produce unapproved generic drugs. The FDA requires these pharmacies to cease production of the generic versions within 60 to 90 days, with the transition period aimed at allowing patients to switch to the brand-name medication. After the announcement, the stock prices of both Eli Lilly and Co and Novo-Nordisk A/S narrowed their declines.
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services